Faculty introduction, disclosures

Introduction content: Cursory refresher and review of postmenopausal osteoporosis Epidemiology Differential diagnosis: Ruling out vitamin D deficiency and other endocrine and metabolic disorders Patient cases

Risk assessment and diagnosis Established and emerging risk factors for postmenopausal osteoporosis and for fracture Bone mineral density, dual-energy X-ray absorptiometry, T-scores, and bone metabolic biomarkers The role of the specialist in community engagement with osteoporosis screening in postmenopausal women Treatment and prevention of osteoporosis Clinical trial findings and guideline updates A review of present pharmacotherapy; present controversies and risks to include: Atrial fibrillation Esophageal cancer Atypical fractures Osteonecrosis of the jaw Acute renal failure REMS guidelines Dermatologic reactions Infections Osteosarcoma Patient education burden Therapies approved in recent years Mechanisms of action Role in management Emerging evidence for use Patient-specific treatment considerations Emerging therapies Optimizing adherence to therapy Patient case(s)

Summary, conclusions, and best practice recap

 

By the end of the session the participant will be able to:

• Recall how the results of diagnostic imaging and pertinent past medical history to determine risk of fracture.
• List the criteria for initiation of pharmacotherapy for postmenopausal osteoporosis treatment and prevention and apply them to a patient case.
• Describe challenges associated with treating patients with postmenopausal osteoporosis, focusing specifically on the risks of the agents used to treat and prevent osteoporosis, and apply the information to optimize patient care in a patient case.
• Identify recently approved and emerging pharmacotherapeutic treatments for management of postmenopausal osteoporosis, and describe their mechanisms of action.

ACCME Activity #201861257

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Violet Lagari, DO, MPH, Associate Professor, University of Miami School of Medicine, Endocrinology Section Chief, Miami VAHS, has no relevent conflicts of interest to disclose.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version